4/A: Processa Director Retracts Prior SEC Filing Due to Error
Beneficial Ownership Amendment
Processa Pharmaceuticals Director Justin W. Yorke filed an amended Form 4 to retract a previously filed beneficial ownership statement, citing an error.
Summary
- Justin W. Yorke, a Director of Processa Pharmaceuticals, Inc. (PCSA), filed a Form 4/A amendment to retract a previously submitted Form 4.
- The original Form 4, filed on July 28, 2025, which reported transactions from July 24, 2025, was filed in error.
- The retracted filing had indicated beneficial ownership of 3,737 shares of Common Stock directly, 12,400 shares indirectly via Directed Trust Company FBO Justin Yorke IRA, and 31,232 shares indirectly via Richland Fund, LLC.
- It also reported indirect beneficial ownership of 12,400 and 6,200 warrants, each with a conversion price of $0.65, exercisable from January 29, 2025, and expiring on January 29, 2030, via Directed Trust Company FBO Justin Yorke IRA.
- The amendment, signed on September 18, 2025, serves to nullify the information contained in the erroneous prior filing.
Sentiment
Score: 5
Explanation: The filing is a neutral administrative correction, retracting a previously filed beneficial ownership statement due to an error. It does not reflect on the company's operational performance or financial health.
Positives
- The reporting person and company are taking corrective action to ensure accuracy in public disclosures by retracting an erroneous filing.
Negatives
- An administrative error led to the filing of an incorrect beneficial ownership statement, requiring a subsequent retraction.
Risks
- Potential for administrative errors in SEC filings, which could lead to temporary misrepresentation of insider ownership.
Future Outlook
NA
Management Comments
- The amendment was filed to retract the prior Form 4, which was filed in error.
Industry Context
This filing is an administrative correction related to insider beneficial ownership and does not directly relate to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides clarity and corrects the public record regarding a director's beneficial ownership, ensuring accurate information is available.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date exercisable and expiration date for warrants (as reported in the retracted filing) |
| 07/24/2025 | Date of earliest transaction reported in the original, now retracted, Form 4 |
| 07/28/2025 | Date of original Form 4 filing that is being retracted |
| 09/18/2025 | Date of the Form 4/A amendment filing |
Keywords
Processa Pharmaceuticals, PCSA, Form 4/A, SEC filing, beneficial ownership, director, insider transaction, amendment, retraction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.